Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) entered into a securities purchase agreement on August 27, 2026 with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof) plus warrants to purchase up to 1,058,517 shares in a private placement.
The combined effective offering price is $5.02 per common share and accompanying warrants, and $5.019 per pre-funded warrant and accompanying warrants. According to Tenon Medical, pre-funded warrants have a $0.001 exercise price, while the other warrants are exercisable at $5.02 for five years. Estimated gross proceeds are about $3.0 million before fees, with closing expected on or about August 31, 2026, subject to customary conditions. WallachBeth Capital is the exclusive placement agent, and the company has agreed to provide customary registration rights for the shares and underlying warrant shares.
Tenon Medical (NASDAQ:TNON) announced that Nasdaq has confirmed the company has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). The company had previously fallen below the threshold for 30 consecutive business days, triggering a Nasdaq notification on February 25, 2026.
According to Tenon Medical, a 1-for-35 reverse stock split effective August 10, 2026 lifted the closing bid price to at least $1.00 for 10 consecutive business days through August 21, 2026, restoring compliance as of August 24, 2026. Tenon’s common stock continues to trade on the Nasdaq Capital Market under the symbol TNON.
Tenon Medical (NASDAQ:TNON) reported second quarter 2026 revenue of $1.3 million, up 127% from $0.6 million a year earlier. Gross profit rose to $0.8 million with gross margin improving to 64% from 43%, driven by higher procedure volume and better overhead absorption.
Operating expenses increased to $4.2 million, leading to a net loss of $4.1 million (‑$12.35 per share) versus a $2.8 million loss in Q2 2025. Cash and equivalents were $1.7 million on June 30, 2026, versus $3.8 million at year‑end, and stockholders’ equity shifted to a $1.7 million deficit.
Subsequent to quarter end, Tenon closed a $4.2 million public offering (about $3.6 million net) to help repay part of its $5.2 million convertible notes maturing in September 2026 and to fund commercial, clinical, and product development efforts. The company also obtained FDA 510(k) clearance for an updated Catamaran SI Joint Fusion System and executed a 1‑for‑35 reverse stock split on August 10, 2026 as it works to regain Nasdaq listing compliance.
Tenon Medical (NASDAQ:TNON) has approved a 1-for-35 reverse stock split of its issued and outstanding common stock, effective at 12:01 a.m. Eastern Time on August 10, 2026. At that time, each 35 pre-split shares will be converted into one post-split share, and trading on the Nasdaq Capital Market will begin on a split-adjusted basis under the existing symbol “TNON” with a new CUSIP 88066N402.
The reverse split, authorized by stockholders on July 23, 2026, is intended to increase the per-share market price to meet Nasdaq’s $1.00 minimum average closing price requirement for continued listing. No fractional shares will be issued; any fractional amounts will be rounded up to the next whole share. Vstock Transfer will act as exchange agent, and most stockholders will not need to take action.
Tenon Medical (NASDAQ:TNON) will release its second quarter 2026 financial results for the period ended June 30, 2026 after market close on Thursday, August 13, 2026, followed by a conference call at 4:30 p.m. Eastern Time featuring a Q&A with covering analysts.
Investors can join via dial-in at 1-877-407-0792 (U.S.) or 1-201-689-8263 (international), or through a webcast titled “TNON Conference Call.” An audio replay will be available until August 27, 2026 on Tenon’s investor relations website or by telephone replay with access code 13761819.
According to Tenon Medical, the company develops medical devices for sacro-pelvic disorders and offers the Catamaran SI Joint Fusion System and, following an August 2025 asset acquisition from SiVantage and SIMPL Medical, the SImmetry+ SI Joint Fusion System.
Tenon Medical (NASDAQ:TNON) reported that Nasdaq notified the company on July 17, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity to maintain listing on the Nasdaq Capital Market.
According to Tenon, this compliance followed a $4.2 million public offering of common stock and warrants completed on July 1, 2026 and disclosed in a July 10, 2026 Form 8-K. Tenon noted that if it does not demonstrate ongoing compliance in its Form 10-Q for the quarter ending September 30, 2026, it may face potential delisting, subject to appeal.
Tenon Medical (NASDAQ:TNON) received FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System. The clearance covers instrument upgrades and reclassification of select tools from disposable to reusable, intended to lower per-procedure costs and support gross margin and cash flow.
The Catamaran system uses a single titanium implant via a minimally invasive, inferior-posterior SI joint approach. Since its October 2022 U.S. launch, over 1,500 Catamaran Fixation Devices have been implanted.
Tenon Medical (NASDAQ:TNON) closed a public offering totaling $4.2 million in gross proceeds. The deal included 11,052,631 common shares (or pre-funded warrants) plus common warrants for up to 13,263,159 shares at a combined price of $0.38 per share and warrant.
Proceeds are earmarked for partial repayment of convertible notes, commercial expansion, clinical research, R&D and product launches, inventory and instrumentation, marketing, working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON) closed a public offering for approximately $4.2 million in gross proceeds. The deal included 11,052,631 common shares (or pre-funded warrants) plus Common Warrants for up to 13,263,159 shares at a combined price of $0.38 per share.
Proceeds are expected to fund partial repayment of convertible notes, commercial expansion, clinician training, added sales reps and distributors, clinical research, R&D for future launches, higher inventory and instrumentation, marketing, working capital and general corporate purposes. Common and pre-funded warrants are immediately exercisable.
Tenon Medical (NASDAQ:TNON) priced a registered public offering for approximately $4.2 million in gross proceeds. The deal includes up to 11,052,631 shares (or pre-funded warrants) plus 13,263,159 common warrants at a combined public price of $0.38 per share and warrant.
According to Tenon, net proceeds will fund partial repayment of convertible notes, commercial expansion, clinical research, R&D for future product launches, inventory and instrumentation, marketing, working capital and general corporate purposes. Common and pre-funded warrants are immediately exercisable.